MedKoo Cat#: 555160 | Name: SCH-336
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SCH-336 is a potent and selective human cannabinoid (hCB2) inverse agonist. SCH-336 is an inverse agonist at hCB2, as shown by its ability to decrease GTPgammaS binding to membranes containing hCB2, by the ability of GTPgammaS to left-shift SCH-336 binding to hCB2 in these membranes, and by the compound's ability to increase forskolin-stimulated cAMP levels in CHO cells expressing hCB2.

Chemical Structure

SCH-336
SCH-336
CAS#447459-51-0

Theoretical Analysis

MedKoo Cat#: 555160

Name: SCH-336

CAS#: 447459-51-0

Chemical Formula: C23H25NO8S3

Exact Mass: 539.0742

Molecular Weight: 539.63

Elemental Analysis: C, 51.19; H, 4.67; N, 2.60; O, 23.72; S, 17.82

Price and Availability

Size Price Availability Quantity
25mg USD 450.00 2 Weeks
50mg USD 750.00 2 Weeks
100mg USD 1,350.00 2 Weeks
200mg USD 2,350.00 2 Weeks
1g USD 4,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
SCH-336; SCH 336; SCH336.
IUPAC/Chemical Name
N-[(1S)-1-[4-[[4-Methoxy-2-[(4-methoxyphenyl)sulfonyl]phenyl]sulfonyl]phenyl]ethyl]methanesulfonamide
InChi Key
NXODIUKWAVUFGF-INIZCTEOSA-N
InChi Code
InChI=1S/C23H25NO8S3/c1-16(24-33(4,25)26)17-5-10-20(11-6-17)34(27,28)22-14-9-19(32-3)15-23(22)35(29,30)21-12-7-18(31-2)8-13-21/h5-16,24H,1-4H3/t16-/m0/s1
SMILES Code
CS(=O)(N[C@H](C1=CC=C(S(=O)(C2=CC=C(OC)C=C2S(=O)(C3=CC=C(OC)C=C3)=O)=O)C=C1)C)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
SCH-336 is a selective CB2 receptor inverse agonist (Ki = 1.8 nM, EC50 = 2 nM). SCH-336 displays 100-fold selectivity for CB2 receptors over CB1. SCH-336 increases Forskolin stimulated cAMP accumulation in CHO cells expressing human CB2 receptors. SCH-336 inhibits leukocyte migration in a murine model of delayed-type hypersensitivity and inhibits antigen-induced lung eosinophilia in a mouse allergy model.
In vitro activity:
To be determined
In vivo activity:
Selective CB2 inverse agonists, like SCH-336, may be promising for treating acute and chronic inflammatory disorders characterized by leukocyte recruitment. Oral administration of SCH-336 significantly inhibited leukocyte trafficking induced by chemokines or antigen challenge in rodent models. SCH-336 blocked ovalbumin-induced lung eosinophilia in a mouse model of allergic asthma. Reference: J Pharmacol Exp Ther. 2006 Feb;316(2):780-8. https://pubmed.ncbi.nlm.nih.gov/16258021/
Solvent mg/mL mM
Solubility
DMSO 54.0 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 539.63 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Lunn CA, Fine JS, Rojas-Triana A, Jackson JV, Fan X, Kung TT, Gonsiorek W, Schwarz MA, Lavey B, Kozlowski JA, Narula SK, Lundell DJ, Hipkin RW, Bober LA. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther. 2006 Feb;316(2):780-8. doi: 10.1124/jpet.105.093500. Epub 2005 Oct 28. PMID: 16258021.
In vitro protocol:
To be determined
In vivo protocol:
1. Lunn CA, Fine JS, Rojas-Triana A, Jackson JV, Fan X, Kung TT, Gonsiorek W, Schwarz MA, Lavey B, Kozlowski JA, Narula SK, Lundell DJ, Hipkin RW, Bober LA. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther. 2006 Feb;316(2):780-8. doi: 10.1124/jpet.105.093500. Epub 2005 Oct 28. PMID: 16258021.
1: Lunn CA, Fine JS, Rojas-Triana A, Jackson JV, Fan X, Kung TT, Gonsiorek W, Schwarz MA, Lavey B, Kozlowski JA, Narula SK, Lundell DJ, Hipkin RW, Bober LA. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther. 2006 Feb;316(2):780-8. Epub 2005 Oct 28. PubMed PMID: 16258021.